

References for

Docket No. 2005D-0330

2005  
D-0330

2005D-0330

BKG 1

## REFERENCES

1. FDA Memorandum: Revised Guideline for the Collection of Platelets, Pheresis - 10/7/1988.
2. FDA Recommendations and Licensure Requirements for Leukocyte-Reduced Blood Products, May 29, 1996.
3. FDA Memorandum to Registered Blood and Source Plasma Establishments, Revision of FDA Memorandum of August 27,1982: Requirements for Infrequent Plasmapheresis Donors - 3/10/1995.
4. FDA Guidance for Industry: Recommendations for Collecting Red Blood Cells by Automated Apheresis Methods - Technical Correction February 2001 - 2/13/2001.
5. Murphy S. Platelet storage for transfusion. *Seminars in Hematology* 1985 July; 22 (3): 165-77.
6. Dumont LJ, VandenBroeke T. Seven-day storage of apheresis platelets: report of an in vitro study. *Transfusion*. 2003 Feb; 43 (2): 143-50.
7. Blajchman MA. Incidence and significance of the bacterial contamination of blood components. *Dev Biol* 2002; 108: 59-67.
8. Hillyer CD, Josephson CD, Blajchman, MA, Vostal JG, Epstein JS, Goodman JL. Bacterial contamination of blood components: risks, strategies, and regulation: Joint ASH and AABB Educational Session in Transfusion Medicine. *Hematology* 2003; 575-89.
9. ASBPO Donor Deferral Criteria: Drugs and Medication Impact on Blood Donor Eligibility. [www.tricare.osd.mil/asbpo/library/policies/downloads/medication\\_list.doc](http://www.tricare.osd.mil/asbpo/library/policies/downloads/medication_list.doc)
10. Patrono C, Coller B, Dalen JE, et al. Platelet-Active drugs. The relationships among dose, effectiveness, and side effects. *Chest* 2001 supplement; 119 (1): 39-63S.
11. Federal Register, Proposed Rules, Vol. 50, No. 247, December 24, 1985.
12. FDA Guideline on General Principles of Process Validation, May 1987, reprinted February 1993.
13. FDA Guidance for Industry: Use of Sterile Connecting Devices in Blood Bank Practices - 11/22/2000.
14. FDA Guideline for Quality Assurance in Blood Establishments, July 11, 1995.
15. Dumont LJ, Dzik WH, Rebullia P, et al. Practical guidelines for process validation and process control of white-cell reduced blood components: report of the Biomedical Excellence for Safer Transfusion (BEST) working party of the International Society of Blood Transfusion (ISBT). *Transfusion* 1996; 36: 11-20.
16. CBER Device Clearances:<http://www.fda.gov/cber/appr2002/2002approv.htm>
17. Brecher ME, Means N, Jere CS et al. Evaluation of an automated culture system for detecting bacterial contamination of platelets: an analysis with 15 contaminating organisms. *Transfusion* 2001 Apr; 41 (4): 477-482.
18. McDonald CP, Roy A, Lowe P, et al. Evaluation of the BacT/Alert automated blood culture system for detecting bacteria and measuring their growth kinetics in leucodepleted and non-leucodepleted platelet concentrates. *Vox Sang*. 2001 Oct; 81(3): 154-60.
19. Brecher ME, Heath DG, Hay SN, et al. Evaluation of a new generation of culture bottle using an automated bacterial culture system for detecting nine common contaminating organisms found in platelet components. *Transfusion*. 2002 Jun; 42(6): 774-9.

20. FDA Draft Guidance for Industry: Biological Product Deviation Reporting for Licensed Manufacturers of Biological Products Other than Blood and Blood Components - 8/10/2001.
21. Lazarus EF, Browning J, Norman J, Oblitas J, Leitman SF. Sustained decreases in platelet count associated with multiple, regular plateletpheresis donations. *Transfusion*. 2001 June; 41: 756-761.
22. Circular of Information for the Use of Human Blood and Blood Components. American Association of Blood Banks, America's Blood Centers, American Red Cross, July, 2002.
23. FDA Guidance for Industry: Changes to an Approved Application: Biological Products: Human Blood and Blood Components Intended for Transfusion or for Further Manufacture - 8/7/2001.
24. Glaz J, Naus J, Wallenstein S. *Scan Statistics* 2001. Springer Publishing.